Baseline characteristics and risk factors for short-term outcomes in 132 COVID-19 patients with diabetes in Wuhan China: A retrospective study

Li, Yumin; Han, Xiaoyu; Alwalid, Osamah; Cui, Yue; Cao, Yukun; Liu, Jia; Gu, Jin; Wang, Lixia; Fan, Yanqing; Shi, Heshui

doi:10.1016/j.diabres.2020.108299

Cited by 51 publications

(47 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A total of 75 articles were excluded on the basis of the full text. Finally, 16 studies [8][9][10][15][16][17][18][19][20][21][22][23][24][25][26] with 6386 COVID-19 patients were eligible and included in the meta-analysis. The process of study selection with reasons for exclusion is shown in Figure 1.…”

Section: Search Resultsmentioning

confidence: 99%

Hyperglycemia at admission is a strong predictor of mortality and severe/critical complications in COVID-19 patients: a meta-analysis

2021

View full text Add to dashboard Cite

Background: Hyperglycaemia at admission has been demonstrated to exacerbate the outcomes of coronavirus disease 2019 (COVID-19) but a meta-analysis is lacking to further confirm this hypothesis. The purpose of this meta-analysis was to summarize the evidence on the association between hyperglycaemia at admission and the development of COVID-19. Method: Four databases namely, PubMed, Web of Science, Embase and Cochrane Library, were screened for eligible studies. STATA software was utilized to pool data for this meta-analysis. The primary outcomes included mortality and severity. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated with random-effects models, and the quality of evidence was appraised by the Newcastle-Ottawa Scale (NOS). This meta-analysis was prospectively registered online on PROSPERO, CRD42020191763. Results: Sixteen observational studies with 6386 COVID-19 patients relating hyperglycaemia at admission to COVID-19 outcomes were included. The overall data demonstrated that, compared with the control, the hyperglycaemia at admission group was more likely to have increased mortality (OR = 3.45, 95% CI, 2.26–5.26) and severe/critical complications (OR = 2.08, 95% CI, 1.45–2.99) of COVID-19. Conclusion: Hyperglycaemia at admission in COVID-19 patients may be a strong predictor of mortality and complications.

show abstract

Section: Search Resultsmentioning

confidence: 99%

Hyperglycemia at admission is a strong predictor of mortality and severe/critical complications in COVID-19 patients: a meta-analysis

2021

View full text Add to dashboard Cite

show abstract

“…The results of our study showed that symptoms of COVID-19, including fever, shortness of breath, and cough, were mostly reported in diabetic patients than in non-diabetic patients, while chest pain, sore throat, and decreased sense of smell and taste were more common in non-diabetic COVID-19 patients. In a study conducted in China, fever, dry cough, and fatigue were the most common symptoms in diabetic COVID-19 patients [ 23 ], and another study showed cough and fever as the most common symptoms in these patients [ 24 ]. A systematic review study indicated that no significant differences in signs and symptoms of these differences may be due to variation in selected sample sizes in various studies, study population, and type of collected data [ 18 ].…”

Section: Discussionmentioning

confidence: 99%

Epidemiological characteristics and outcomes of COVID-19 in diabetic versus non-diabetic patients

Moftakhar¹,

Moftakhar

Piraee

et al. 2021

Int J Diabetes Dev Ctries

View full text Add to dashboard Cite

Objectives and background People with diabetes (PWD) are one of the high-risk groups for coronavirus disease 2019 (COVID-19) infection, increasing the disease mortality. This study was aimed to compare the epidemiological characteristics and outcomes of COVID-19 in diabetic versus non-diabetic individuals. Methods In this retrospective observational study, the epidemiological characteristics of the two groups of diabetic ( n =1365) and non-diabetic ( n =15,026) subjects with definite diagnosis of COVID-19 in the southwestern region of Iran were compared. All clinical signs and comorbidities of the patients were evaluated. Chi-square test was used to examine the differences in qualitative variables between diabetic and non-diabetic groups. Results Of 16,391 enrolled subjects, 8.3% had diabetes, and 28.3% of COVID-19-related deaths occurred in diabetics. Also, the mortality rate among diabetics was reported as 14.3%. The average age of diabetic patients and non-diabetic patients was 59 and 37 years, respectively. The odds of fever, cough, shortness of breath, headache, and underlying diseases, such as hypertension, cardiovascular disease, chronic lung disease, immune deficiency, and hyperlipidemia, were significantly higher in diabetic patients than in non-diabetics. Conclusion Diabetes is associated with increased mortality rate in patients with COVID-19 and is considered as a major risk factor for COVID-19 infection, posing a major public health challenge for health policymakers in managing and controlling the disease. Therefore, development of prevention and treatment strategies aimed at reducing COVID-19 morbidity and mortality in diabetes patients is of significant importance.

show abstract

“…These measurements taken at day 0 and day 4 provide an early and noninvasive indication of progression of disease to a severe course 229 . In addition, the semi‐quantitative CT pneumonia score is a valuable tool to help clinicians identify patients at higher risk of complications and mortality 113,230 . AI algorithms can identify important clinical markers correlated with COVID‐19 pneumonia lesions and also provide accurate clinical prognosis that can aid clinicians to provide risk‐stratified treatment 42 …”

Section: Laboratory Indicatorsmentioning

confidence: 99%

Risk factors for severe and critically ill COVID‐19 patients: A review

Gao

Ding

Dong

et al. 2020

Allergy

1,166

864

View full text Add to dashboard Cite

The pandemic of coronavirus disease 2019 (COVID‐19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), has caused an unprecedented global social and economic impact, and high numbers of deaths. Many risk factors have been identified in the progression of COVID‐19 into a severe and critical stage, including old age, male gender, underlying comorbidities such as hypertension, diabetes, obesity, chronic lung diseases, heart, liver and kidney diseases, tumors, clinically apparent immunodeficiencies, local immunodeficiencies, such as early type I interferon secretion capacity, and pregnancy. Possible complications include acute kidney injury, coagulation disorders, thoromboembolism. The development of lymphopenia and eosinopenia are laboratory indicators of COVID‐19. Laboratory parameters to monitor disease progression include lactate dehydrogenase, procalcitonin, high‐sensitivity C‐reactive protein, proinflammatory cytokines such as interleukin (IL)‐6, IL‐1β, Krebs von den Lungen‐6 (KL‐6), and ferritin. The development of a cytokine storm and extensive chest computed tomography imaging patterns are indicators of a severe disease. In addition, socioeconomic status, diet, lifestyle, geographical differences, ethnicity, exposed viral load, day of initiation of treatment, and quality of health care have been reported to influence individual outcomes. In this review, we highlight the scientific evidence on the risk factors of severity of COVID‐19.

show abstract

Baseline characteristics and risk factors for short-term outcomes in 132 COVID-19 patients with diabetes in Wuhan China: A retrospective study

Cited by 51 publications

References 34 publications

Hyperglycemia at admission is a strong predictor of mortality and severe/critical complications in COVID-19 patients: a meta-analysis

Hyperglycemia at admission is a strong predictor of mortality and severe/critical complications in COVID-19 patients: a meta-analysis

Epidemiological characteristics and outcomes of COVID-19 in diabetic versus non-diabetic patients

Risk factors for severe and critically ill COVID‐19 patients: A review

Contact Info

Product

Resources

About